Freedom Broker keeps INmune Bio at Buy, cuts price target to $2.50
Freedom Broker kept its Buy rating on INmune Bio and lowered the price target 37.5%, from $4 to $2.50. Data from TradingView, with Benzinga as the source.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Freedom Broker analysts kept their Buy rating on INmune Bio shares but reduced the price target from $4 to $2.50, a 37.5% cut. According to TradingView, which cites Benzinga, the new target implies an upside of 138.1% from the November 12 close of $1.05.
The update reflects a single analyst's revised valuation and contains no separate corporate news about the company.
why it matters
Price target revisions like this usually affect one stock and rarely move the broader market. A lower target alongside an unchanged Buy rating suggests the analyst revised its valuation model without changing its overall view of the company. Investors may want to compare such estimates with financial reports and other sources.
tags
instruments
sources
- Freedom Broker maintains INmune Bio at Buy, lowers price target to $2.50 from $4 — TradingView, 13 November 2026 at 19:26 UTC
- Freedom Broker maintains Douglas Dynamics at Buy, lowers price target to $55 from $56 — TradingView, 13 November 2026 at 19:29 UTC
- Freedom Broker maintains Lifevantage at Buy, lowers price target to $8 from $9 — TradingView, 13 November 2026 at 19:32 UTC
- INmune Bio Price Target Cut to $2.50/Share From $4.00 by Freedom Broker — Dow Jones Newswires, 13 November 2026 at 19:37 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗